Alaunos Therapeutics, Inc. (TCRT)
Stock analysis · NASDAQ · Healthcare · Biotechnology
Alaunos Therapeutics, Inc. (TCRT) is a publicly traded company in the Healthcare sector. Latest price: $2.06. Market cap $6.03M. Trailing PE -1.06. Sign in to Stocks360 for full DCF valuation, fundamentals, technicals, and AI-driven analysis.
Get full analysis → Short-Term Analysis →1-Year Price
Earnings
Proprietary Signals
About Alaunos Therapeutics, Inc.
Alaunos Therapeutics, Inc. is an oncology company in the clinical trial phase, specializing in the creation of adoptive T-cell receptor (TCR) engineered therapies. Their pipeline includes a TCR Library, currently undergoing Phase I/II clinical trials, which comprises ten T-cell receptors designed to target mutated KRAS, TP53, and EGFR in various cancers such as non-small cell lung, colorectal, endometrial, pancreatic, ovarian, and bile duct cancers. Additionally, they are advancing hunTR, a platform focused on human neoantigen T-cell receptors, and mbIL-15, intended for solid tumor treatment. The company maintains strategic collaborations, including a licensing agreement with PGEN Therapeutics, Inc., a research and development partnership with The University of Texas MD Anderson Cancer Center, and both a patent licensing and R&D agreement with the National Cancer Institute. Previously known as ZIOPHARM Oncology, Inc., the company adopted its current name, Alaunos Therapeutics, Inc., in January 2022. Its headquarters are located in Houston, Texas.
Valuation
| P/E (TTM) | -1.06× |
|---|---|
| P/S (TTM) | 2009.97× |
| P/B | 7.68× |
| P/FCF (TTM) | -2.13× |
| EV / EBITDA | -1.48× |
| EV / Sales | 1968.63× |
| Earnings Yield | -80.05% |
| Free Cash Flow Yield | -46.85% |
Fundamentals
| Enterprise Value | $5.91M |
|---|---|
| Revenue (TTM) | $3.00K |
| Net Income (TTM) | -$4.83M |
| Free Cash Flow (TTM) | -$2.82M |
| Net Debt | -$124.00K |
| Working Capital | -$198.00K |
| Gross Margin | -28133.33% |
| Operating Margin | -135266.67% |
| Net Margin | -133666.67% |
| Return on Equity | -232.60% |
| Return on Invested Capital | -622.39% |
Peers
Recent News
- Why is Alaunos Therapeutics Stock Trading 200% Higher on Tuesday?
- Alaunos Therapeutics Announces Acquisition of Velaris Therapeutics
- Paragon Labs Expands Leadership Team with Former Apogee Executives; Velaris Therapeutics Acquired by Alaunos Therapeutics, Inc.
- Alaunos Therapeutics, Inc. Announces Pricing of Registered Direct Offering priced at-the-market under Nasdaq rules
- Why Alaunos Therapeutics Shares Are Trading Higher By Around 22%; Here Are 20 Stocks Moving Premarket
Related
Browse more tickers: sitemap